PT-141 vs Melanotan 2

PT-141 vs Melanotan 2: Overview

PT-141 (bremelanotide) and Melanotan 2 (melanotan II, MT-II) are both synthetic melanocortin receptor agonists derived from the naturally occurring alpha-melanocyte-stimulating hormone (α-MSH). While these peptides share a common pharmacological lineage and act on overlapping receptor targets, they have diverged significantly in terms of research focus, clinical development, and regulatory status. Understanding the distinction between PT-141 vs melanotan-2 is essential for appreciating how subtle structural modifications to melanocortin peptides can yield markedly different pharmacological profiles and therapeutic trajectories.

Melanotan 2 was originally developed as a synthetic analogue of α-MSH at the University of Arizona in the 1980s, with the primary objective of inducing skin pigmentation as a potential photoprotective strategy. The peptide demonstrated broad melanocortin receptor affinity, activating multiple receptor subtypes (MC1R through MC5R) and producing a range of effects including skin darkening, appetite suppression, and sexual arousal. Bremelanotide (PT-141), by contrast, is a metabolite of melanotan II that was subsequently developed as a more targeted therapeutic agent. Following observations during melanotan II research that subjects experienced pro-sexual effects, PT-141 was isolated and optimised specifically for this indication.

The most significant difference between melanotan 2 vs PT-141 lies in their respective regulatory trajectories. PT-141 (bremelanotide) received FDA approval in 2019 for the treatment of hypoactive sexual desire disorder (HSDD) in premenopausal women, making it the only melanocortin-based peptide to achieve regulatory approval for a sexual health indication. Melanotan II, meanwhile, has never received regulatory approval for any indication and remains an investigational compound studied primarily in preclinical and early clinical research contexts.

Mechanism of Action

Both PT-141 and melanotan 2 function as agonists of the melanocortin receptor family, a group of five G protein-coupled receptors (MC1R–MC5R) that mediate diverse physiological functions including pigmentation, energy homeostasis, inflammation, and sexual function. However, their receptor selectivity profiles differ in ways that are pharmacologically significant.

Melanotan II is a non-selective melanocortin receptor agonist with potent activity at MC1R (pigmentation), MC3R (energy homeostasis), MC4R (appetite, sexual function), and MC5R (exocrine gland function). This broad receptor engagement explains the wide range of effects observed with melanotan II, from skin tanning to appetite suppression to pro-sexual effects. Weirath and Haskell-Luevano (2024) provided a comprehensive review of melanocortin receptor tool compounds, characterising melanotan II as a versatile but non-selective MCR agonist. The cyclic heptapeptide structure of melanotan II, incorporating the key Nle4-DPhe7 modifications to the α-MSH core pharmacophore, confers enhanced receptor binding potency and resistance to enzymatic degradation.

Bremelanotide (PT-141), while structurally derived from melanotan II, demonstrates a somewhat different receptor activation profile. Research suggests that its pro-sexual effects are mediated primarily through activation of MC4R in the central nervous system, particularly in brain regions associated with sexual arousal and desire. Borland et al. (2025) examined bremelanotide’s mechanisms using Syrian hamster models, providing preclinical evidence for its effects on neural circuits implicated in sexual motivation. Ford et al. (2024) demonstrated that melanocortin agonism in a social context selectively activates the nucleus accumbens in an oxytocin-dependent manner, suggesting that the pro-sexual effects of melanocortin vs bremelanotide may involve complex interactions between melanocortin and oxytocin signalling pathways.

Clinical Evidence

The clinical evidence supporting PT-141 (bremelanotide) is substantially more robust than that available for melanotan 2, reflecting its progression through formal pharmaceutical development and regulatory review.

Bremelanotide was evaluated in the RECONNECT programme, comprising two pivotal Phase 3 randomised, double-blind, placebo-controlled trials in premenopausal women with hypoactive sexual desire disorder. Kingsberg et al. (2019) reported the results of these trials, demonstrating statistically significant improvements in sexual desire and reductions in distress related to low sexual desire compared with placebo. Simon et al. (2019) subsequently published long-term safety and efficacy data, confirming that the therapeutic benefits of bremelanotide were maintained over extended treatment periods. Pre-specified subgroup analyses from the RECONNECT studies, published by Simon et al. (2022), further characterised the response patterns across different patient populations.

Melanotan II has been evaluated in smaller-scale human studies, primarily focused on its pigmentation effects. Clinical investigations in volunteers demonstrated dose-dependent increases in skin melanin content following subcutaneous administration. However, these studies were limited in scope and did not meet the evidentiary standards required for regulatory approval. The most extensively documented effects of melanotan II in human subjects relate to its tanning properties, which have been the subject of both clinical research and considerable public health concern due to the widespread unregulated use of melanotan II as a cosmetic tanning agent.

A critical independent analysis by Spielmans (2021) re-examined the Phase 3 bremelanotide trial data, questioning the magnitude of clinical benefit observed. Spielmans and Ellefson (2024) subsequently published further critique, characterising the treatment effects as statistically significant but clinically modest. These analyses highlight the ongoing academic debate around the clinical meaningfulness of bremelanotide’s efficacy.

Efficacy Comparison

Direct efficacy comparisons between PT-141 vs melanotan-2 are complicated by the fact that these peptides have been evaluated for different primary endpoints. Bremelanotide’s efficacy has been measured primarily in terms of improvements in sexual desire scores and reductions in sexual distress, while melanotan II’s efficacy has been assessed predominantly through changes in skin melanin density.

For sexual function effects, bremelanotide demonstrated consistent improvements in the Female Sexual Function Index–desire domain and reductions in the Female Sexual Distress Scale–Desire/Arousal/Orgasm scores across the RECONNECT trials. While melanotan II also produced pro-sexual effects in early research, these were observed as secondary endpoints and were not the focus of rigorous controlled clinical evaluation.

For pigmentation effects, melanotan II appears to be more potent than bremelanotide in inducing skin darkening, which is consistent with its stronger MC1R agonist activity. This difference reflects the design intent of each peptide: melanotan II was developed as a broad melanocortin agonist targeting pigmentation, while bremelanotide was optimised for MC4R-mediated sexual function effects with reduced peripheral activity.

Preclinical research has explored additional applications for both peptides. Inozemtseva et al. (2024) investigated the antidepressant-like and antistress effects of melanotan II in a chronic unpredictable stress model in rats, suggesting potential neuropsychiatric applications beyond its pigmentation and sexual effects. Suzuki et al. (2024) examined bremelanotide’s ability to induce cell death in glioblastoma cells, indicating possible oncological research interest.

Safety and Tolerability

The safety profiles of these two peptides reflect their different receptor selectivity patterns and routes of development. Bremelanotide has the more comprehensively characterised safety profile, having undergone formal Phase 3 clinical evaluation and post-marketing surveillance.

Common adverse effects reported with bremelanotide include nausea, flushing, and injection-site reactions. Nausea was the most frequently reported adverse event in the RECONNECT trials, occurring in a significant proportion of treated subjects, though it tended to diminish with continued use. Importantly, bremelanotide carries labelling warnings regarding transient increases in blood pressure, which preclude its use in patients with uncontrolled hypertension or significant cardiovascular disease. Barakeh et al. (2024) provided a comprehensive review of the pharmacotherapy landscape for HSDD in premenopausal women, contextualising bremelanotide’s safety profile within the broader treatment options available.

Melanotan II’s safety profile is less well characterised through formal clinical evaluation but has been documented through case reports, observational studies, and qualitative research. Documented adverse effects include nausea, facial flushing, fatigue, and notably, changes in melanocytic nevi. Bonchev (2026) reported changes in oral mucosa associated with melanotan II use, while Yassin Alsabbagh et al. (2025) discussed a possible association between melanotan II nasal spray and oral mucosal melanoma, raising significant safety concerns. Gilhooley et al. (2021) conducted a qualitative study of online melanotan II user experiences, documenting the range of self-reported side effects in unregulated use settings. The potential for melanotan II to alter melanocytic nevi has prompted dermatological concern about potential melanoma risk, though a causal relationship has not been definitively established.

Pharmacokinetics

Bremelanotide is administered via subcutaneous auto-injection, with a bioavailability of approximately 100% following subcutaneous dosing. It reaches peak plasma concentrations within approximately one hour and has a terminal half-life of approximately 2.7 hours. The peptide is primarily eliminated through hydrolysis to constituent amino acids, with minimal involvement of hepatic cytochrome P450 enzymes. This pharmacokinetic profile supports its use as an on-demand treatment, administered as needed before anticipated sexual activity.

Melanotan II has been investigated via subcutaneous injection as well as intranasal administration, though neither route has been formally approved. Its cyclic structure provides some resistance to enzymatic degradation, contributing to a somewhat longer duration of action compared to linear peptides. The pharmacokinetics of melanotan II have been less rigorously characterised in formal human studies, and much of the available information is derived from preclinical data and analytical detection studies such as those by Deville and Charlier (2024), who developed forensic identification methods for melanotan II.

A key pharmacokinetic distinction is that bremelanotide is a metabolite of melanotan II, which suggests that some of the effects observed following melanotan II administration may be partially mediated by its conversion to bremelanotide in vivo. This metabolic relationship further complicates direct pharmacokinetic comparisons between the two compounds.

Current Research Status

Bremelanotide (PT-141) received FDA approval in June 2019 under the brand name Vyleesi® for the treatment of acquired, generalised HSDD in premenopausal women. This approval was based on the RECONNECT Phase 3 clinical programme, making bremelanotide the first and only melanocortin receptor agonist approved for a sexual health indication. The peptide is not approved for use in men or postmenopausal women, though research interest in broader applications continues.

Melanotan II has no regulatory approval in any jurisdiction for any indication. Its closest structural relative in the regulatory space is afamelanotide (a melanotan I analogue), which received FDA approval in 2019 for the prevention of phototoxicity in adults with erythropoietic protoporphyria, a distinct indication unrelated to cosmetic tanning.

Current research on melanocortin receptor agonists continues to explore their roles in diverse physiological systems. Sweeney et al. (2023) reviewed the central melanocortin system as a target for metabolic disorders, highlighting the ongoing interest in developing more selective melanocortin agonists and antagonists for various therapeutic applications. The melanocortin system’s involvement in energy homeostasis, inflammation, pigmentation, and sexual function ensures continued research interest in both established and novel melanocortin peptide analogues.

Public health agencies in multiple countries have issued warnings about unregulated melanotan II products, citing concerns about product quality, contamination, and the absence of controlled safety data. The self-administration of unregulated melanotan II remains a significant public health concern, particularly in the cosmetic tanning context.

Summary

PT-141 (bremelanotide) and melanotan 2 are structurally related melanocortin receptor agonists that have followed very different development paths. Melanotan 2 is a broad-spectrum MCR agonist producing pigmentation, appetite, and sexual effects, while bremelanotide is a metabolite of melanotan II that was specifically developed and approved for hypoactive sexual desire disorder. The key difference between melanotan 2 vs PT-141 is regulatory status: bremelanotide received FDA approval in 2019 following rigorous Phase 3 clinical trials, while melanotan II remains unapproved and has generated safety concerns related to unregulated use. Both peptides highlight the therapeutic potential of the melanocortin system, though their contrasting regulatory histories underscore the importance of formal clinical evaluation and regulatory oversight in peptide therapeutics development.

References

• Kingsberg SA, Clayton AH, Portman D et al. (2019). Bremelanotide for the Treatment of Hypoactive Sexual Desire Disorder: Two Randomized Phase 3 Trials. Obstet Gynecol. PMID: 31599840
• Simon JA, Kingsberg SA, Portman D et al. (2019). Long-Term Safety and Efficacy of Bremelanotide for Hypoactive Sexual Desire Disorder. Obstet Gynecol. PMID: 31599847
• Spielmans GI. (2021). Re-Analyzing Phase III Bremelanotide Trials for “Hypoactive Sexual Desire Disorder” in Women. J Sex Res. PMID: 33678061
• Simon JA, Kingsberg SA, Portman D et al. (2022). Prespecified and Integrated Subgroup Analyses from the RECONNECT Phase 3 Studies of Bremelanotide. J Womens Health. PMID: 35230162
• Gilhooley E, Daly S, McKenna D. (2021). Melanotan II User Experience: A Qualitative Study of Online Discussion Forums. Dermatology. PMID: 34464955
• Sweeney P, Gimenez LE, Hernandez CC et al. (2023). Targeting the central melanocortin system for the treatment of metabolic disorders. Nat Rev Endocrinol. PMID: 37365323
• Inozemtseva LS et al. (2024). Antidepressant-like and antistress effects of the ACTH(4-10) synthetic analogs Semax and Melanotan II on male rats in a model of chronic unpredictable stress. Eur J Pharmacol. PMID: 39442746
• Weirath NA, Haskell-Luevano C. (2024). Recommended Tool Compounds for the Melanocortin Receptor (MCR) G Protein-Coupled Receptors (GPCRs). ACS Pharmacol Transl Sci. PMID: 39296259
• Spielmans GI, Ellefson EM. (2024). Small Effects, Questionable Outcomes: Bremelanotide for Hypoactive Sexual Desire Disorder. J Sex Res. PMID: 36809187
• Ford CL et al. (2024). Melanocortin agonism in a social context selectively activates nucleus accumbens in an oxytocin-dependent manner. Neuropharmacology. PMID: 38253222
• Borland JM et al. (2025). Female Syrian hamster analyses of bremelanotide, a US FDA approved drug for the treatment of female hypoactive sexual desire disorder. Neuropharmacology. PMID: 39793696
• Deville M, Charlier C. (2024). Barbie drug identification: Not a child’s play. J Forensic Sci. PMID: 39302005
• Yassin Alsabbagh A, Bhujel N, Singh RP. (2025). Melanotan II nasal spray: a possible risk factor for oral mucosal malignant melanoma? Int J Oral Maxillofac Surg. PMID: 40210573
• Bonchev A. (2026). Changes in Oral Mucosa Associated with Melanotan II Injections: A Case Report. Life (Basel). PMID: 41752902
• Barakeh D, Mdaihly H, Karaoui LR. (2024). Pharmacotherapy of Hypoactive Sexual Desire Disorder in Premenopausal Women. Ann Pharmacother. PMID: 38767282
• Suzuki S, Kitanaka C, Okada M. (2024). Melanocortin Receptor Agonist Bremelanotide Induces Cell Death and Growth Inhibition in Glioblastoma Cells via Suppression of Survivin Expression. Anticancer Res. PMID: 39197897